Mutation analysis of the MSMB gene in familial prostate cancer

被引:16
|
作者
Kote-Jarai, Z. [1 ]
Leongamornlert, D. [1 ]
Tymrakiewicz, M. [1 ]
Field, H. [2 ]
Guy, M. [1 ]
Al Olama, A. A. [3 ]
Morrison, J. [2 ]
O'Brien, L. [1 ]
Wilkinson, R. [1 ]
Hall, A. [1 ]
Sawyer, E. [1 ]
Muir, K. [4 ]
Hamdy, F. [5 ]
Donovan, J. [6 ]
Neal, D. [7 ,8 ,9 ,10 ]
Easton, D. [3 ]
Eeles, R. [1 ,11 ]
机构
[1] Inst Canc Res, Translat Canc Genet Team, Sutton SM2 5NG, Surrey, England
[2] Univ Cambridge, Strangeways Lab, Dept Oncol, Cambridge CB1 8RN, England
[3] Univ Cambridge, Strangeways Lab, CR UK Genet Epidemiol Unit, Cambridge CB1 8RN, England
[4] Univ Nottingham, Sch Med, Queens Med Ctr, Nottingham NG7 2UH, England
[5] Univ Oxford, Nuffield Dept Surg, Oxford OX3 9DU, England
[6] Univ Bristol, Dept Social Med, Bristol, Avon, England
[7] Univ Cambridge, Addenbrookes Hosp, Dept Oncol, Cambridge CB2 2QQ, England
[8] Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England
[9] Canc Res UK Cambridge Res Inst, Cambridge CB2 0RE, England
[10] Li Ka Shing Ctr, Cambridge CB2 0RE, England
[11] Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England
关键词
MSMB; prostate cancer; SNP; in silico; gene expression; FUNCTIONAL-ANALYSIS; SECRETORY PROTEIN; ASSOCIATION; SUSCEPTIBILITY; VARIANT; RISK;
D O I
10.1038/sj.bjc.6605485
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: MSMB, a gene coding for beta-microseminoprotein, has been identified as a candidate susceptibility gene for prostate cancer (PrCa) in two genome-wide association studies (GWAS). SNP rs10993994 is 2 bp upstream of the transcription initiation site of MSMB and was identified as an associated PrCa risk variant. The MSMB protein is underexpressed in PrCa and it was previously proposed to be an independent marker for the recurrence of cancer after radical prostatectomy. METHODS: In this study, the coding region of this gene and 1500 bp upstream of the 5'UTR has been sequenced in germline DNA in 192 PrCa patients with family history. To evaluate the possible effects of these variants we used in silico analysis. RESULTS: No deleterious mutations were identified, however, nine new sequence variants were found, most of these in the promoter and 5'UTR region. In silico analysis suggests that four of these SNPs are likely to have some effect on gene expression either by affecting ubiquitous or prostate-specific transcription factor (TF)-binding sites or modifying splicing efficiency. INTERPRETATION: We conclude that MSMB is unlikely to be a familial PrCa gene and propose that the high-risk alleles of the SNPs in the 5'UTR effect PrCa risk by modifying MSMB gene expression in response to hormones in a tissue-specific manner. British Journal of Cancer (2010) 102, 414-418. doi:10.1038/sj.bjc.6605485 www.bjcancer.com Published online 8 December 2009 (C) 2010 Cancer Research UK
引用
收藏
页码:414 / 418
页数:5
相关论文
共 50 条
  • [21] Evaluation of MSMB and prostate cancer etiology and severity in a multiethnic population
    Lynch, Shannon
    Walker, Amy
    Spangler, Elaine
    Coomes, Margerie
    Malkowicz, S. Bruce
    Zeigler-Johnson, Charnita
    Rebbeck, Timothy
    CANCER RESEARCH, 2009, 69
  • [22] Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer
    Yeager, Meredith
    Deng, Zuoming
    Boland, Joseph
    Matthews, Casey
    Bacior, Jennifer
    Lonsberry, Victor
    Hutchinson, Amy
    Burdett, Laura A.
    Qi, Liqun
    Jacobs, Kevin B.
    Gonzalez-Bosquet, Jesus
    Berndt, Sonja I.
    Hayes, Richard B.
    Hoover, Robert N.
    Thomas, Gilles
    Hunter, David J.
    Dean, Michael
    Chanock, Stephen J.
    HUMAN GENETICS, 2009, 126 (06) : 743 - 750
  • [23] Consequences of RNASEL gene in familial prostate cancer in Japan
    Suzuki, K
    Nakazato, H
    Ohtake, N
    Matsui, H
    Takei, T
    Nakata, S
    Yamanaka, H
    JOURNAL OF UROLOGY, 2003, 169 (04): : 75 - 75
  • [24] BRCA1 gene mutation carrier analysis in familial breast cancer patients
    Caligo, MA
    Ghimenti, C
    Ricci, S
    Antonuzzo, A
    Marchetti, V
    Allegrini, G
    Cipollini, G
    Maresi, MP
    Olsen, R
    McClure, M
    Frye, C
    ShattuckEidens, D
    Neuhausen, S
    Skolnick, M
    Conte, PF
    Bevilacqua, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 449 - 449
  • [25] Mutation and Polymorphism Analysis of Androgen Receptor Gene in Prostate Cancer Patients in Indonesia
    Utomo, A. B.
    Marwan, D. W.
    Aulaniam, A.
    Widodo, M. A.
    Purnomo, B. B.
    Panigoro, R.
    Sribudiani, Y.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 596 - 597
  • [26] Mutation and microsatellite instability analysis of the androgen receptor gene in human prostate cancer
    Uchida, T
    Wang, CX
    Sato, T
    Muramoto, M
    Iwamura, M
    Egawa, S
    Koshiba, K
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1997, 11 (03) : 551 - 556
  • [27] Germline mutation analysis of the androgen receptor gene in Finnish patients with prostate cancer
    Koivisto, PA
    Hyytinen, ER
    Matikainen, M
    Tammela, TLJ
    Ikonen, T
    Schleutker, J
    JOURNAL OF UROLOGY, 2004, 171 (01): : 431 - 433
  • [28] Mutation analysis of the BRG1 gene in prostate cancer clinical samples
    Valdman, A
    Nordenskjöld, A
    Fang, XL
    Naito, A
    Al-Shukri, S
    Larsson, C
    Ekman, P
    Li, CD
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2003, 22 (05) : 1003 - 1007
  • [29] Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer
    Hunter, Sally M.
    Rowley, Simone M.
    Clouston, David
    Li, Jason
    Lupat, Richard
    Krishnananthan, Nishanth
    Risbridger, Gail
    Taylor, Renea
    Bolton, Damien
    Campbell, Ian G.
    Thorne, Heather
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (03) : 120.e9 - 120.e16
  • [30] Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3
    Dahlman, A.
    Edsjo, A.
    Hallden, C.
    Persson, J. L.
    Fine, S. W.
    Lilja, H.
    Gerald, W.
    Bjartell, A.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2010, 13 (04) : 369 - 375